ISP and Wacker form a strategic alliance
US company International Specialty Products (ISP), of New Jersey, and Munich-based Wacker-Chemie have entered into a global marketing agreement. Effective from the beginning of August, the move gives ISP worldwide rights, excluding Japan, to market, sell and distribute Wacker's range of Cavamax products for use in a variety of pharmaceutical applications. Cavamax cyclodextrins form complexes with medicinal drugs to provide innovative solutions for the pharmaceutical formulator; benefits include increased drug bioavailability, controlled drug release, taste and odour masking and drug stabilisation.
'Our alliance with Wacker enables us to add a new and exciting product line to broaden our pharmaceutical product portfolio, and at the same time it gives Wacker access to ISP's global pharmaceutical technical and marketing expertise and a ready market for its latest technology development,' said Roger Cope, sr vice president, ISP Europe.
Dr Stefan Neumann, head of market development Europe for biotechnology at Wacker-Chemie, believes that ISP's position in the global pharmaceutical excipients business will provide fast-track development of the market for Cavamax.